FRIDAY, July 23, 2021 (HealthDay News) — The controversial new Alzheimer’s drug Aduhelm is creating something of a civil war in medicine, as health networks, hospitals, insurers and individual doctors weigh impending discussions with patients about whether they should take the medication. Many doctors believe the U.S. Food and DrugContinue Reading
FRIDAY, July 23, 2021 (HealthDay News) — A drug that eases hallucinations in people with Parkinson’s disease may be able to do the same for those with dementia, a new clinical trial finds. The medication, called Nuplazid (pimavanserin), is already approved in the United States for treating hallucinations and delusionsContinue Reading
WEDNESDAY, July 21, 2021 (HealthDay News) — Dementia is largely a disease of old age, but a new study finds that up to 5% of all cases are among people in the prime of their lives. Looking at 95 international studies, researchers estimated that nearly 4 million people worldwide areContinue Reading
MONDAY, July 19, 2021 (HealthDay News) — What’s better — a long life or quality of life? New research suggests that people balance both when thinking about their desired life span, and fears of suffering dementia or chronic pain in old age tend to limit how long they want toContinue Reading
THURSDAY, July 15, 2021 (HealthDay News) — Two major U.S. health systems say they will not administer the controversial new Alzheimer’s drug Aduhelm. The decisions by the Cleveland Clinic and Mount Sinai’s Health System in New York City are the latest fallout from the U.S. Food and Drug Administration’s widelyContinue Reading
THURSDAY, July 15, 2021 (HealthDay News) — An active mind in old age may delay Alzheimer’s disease by up to five years, a new study suggests. Activities like reading, writing letters, playing cards or doing puzzles may prolong brain health even for those in their 80s, researchers say. “The keyContinue Reading
TUESDAY, July 13, 2021 (Healthday News) — Medicare launched a formal process on Monday that will determine whether the agency will cover Aduhelm, the newly approved Alzheimer’s drug whose high price tag and unproven benefits have prompted widespread controversy. Medicare’s announcement came the same day that leaders of two HouseContinue Reading
MONDAY, July 12, 2021 (Healthday News) — The U.S. Food and Drug Administration’s controversial approval of the Alzheimer’s drug Aduhelm should be investigated by the Office of Inspector General (OIG), FDA Acting Commissioner Dr. Janet Woodcock has said. The FDA approved Aduhelm even though an advisory panel of outside expertsContinue Reading
THURSDAY, July 8, 2021 (HealthDay News) — The U.S. Food and Drug Administration on Thursday issued new prescribing rules for the controversial Alzheimer’s medication Aduhelm that will likely limit its use. When first approved a month ago, the FDA said Biogen’s monthly IV drug was for all Alzheimer’s patients. TheContinue Reading
THURSDAY, July 1, 2021 (Healthday News) — The U.S. Food and Drug Administration’s controversial approval of a new Alzheimer’s drug, along with its high price, is now being investigated by two House committees. “We have serious concerns about the steep price of Biogen’s new Alzheimer’s drug Aduhelm and the processContinue Reading